Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
Earnings Data
Report Date
Apr 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.4Last Year’s EPS
0.41Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced mix of operational progress and commercial momentum (product relaunches, new launches, leadership additions, supply improvements and modest revenue guidance), alongside material near-term financial and operational challenges (organic revenue declines, margin compression from remediation and tariffs, negative cash conversion in Q4 and elevated leverage). Management emphasized remediation, supply recovery and disciplined capital allocation with a clear plan to delever and improve free cash flow in 2026, but several uncertainties (tariff treatment, MediHoney timing and staged product ramp) keep the near-term outlook cautious.Company Guidance
Fourth Quarter Revenue and EPS Beat
Q4 2025 revenue of $435.0M and adjusted EPS of $0.83, both above the midpoint of guidance; sequential revenue improvement of $33M versus Q3 indicating improving supply and seasonality.
Full Year Reported Revenue Growth
Full year 2025 reported revenue of $1.635B, up 1.5% year-over-year, with reported growth supported by the Acclarent acquisition.
Operational and Quality Progress
Strengthened quality management system, advanced compliance master plan and risk-based remediation, maintained constructive engagement with the FDA, and saw improvements in supply reliability and manufacturing resiliency (yield and safety stock improvements).
Product Relaunches and New Commercial Activity
Early relaunch of PriMatrix and Durepair with strong customer reception; launched MAYFIELD Ghost in the U.S. and received expanded indication for CUSA Clarity in cardiac surgery; progressed clinical evidence programs including AERA pediatric registry.
Segment & Product-Level Outperformance
Double-digit growth in CereLink, MAYFIELD Capital, Aurora, DuraSorb programmable valves and 6 pressure valves; above-market growth in DuraGen and Jarit instruments; CSS global neurosurgery delivered 1.4% organic growth with international high single-digit growth and double-digit growth in China and Canada.
Braintree Facility and SurgiMend Roadmap
Braintree manufacturing facility on track to be operational by end of June 2026 (process validations underway) and plan to return SurgiMend to market in Q4 2026 upon PMA approvals.
Leadership and R&D Investment
Added six executive leaders and a Chief Technology Officer (Teshtar Elavia) to strengthen R&D, program management and innovation focus—positioned to accelerate product pipeline and clinical evidence generation.
2026 Financial Outlook and Deleveraging Plan
Full-year 2026 revenue guidance of $1.66B–$1.70B (reported growth 1.6%–4.1%, organic growth 0.8%–3.3%); adjusted EPS guidance $2.30–$2.40 with expected EBITDA margin improvement of ~40 bps and expectation to materially reduce leverage toward 2.5x–3.5x target by year-end 2026.
IART Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IART Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $11.59 | $11.33 | -2.24% |
Oct 30, 2025 | $15.43 | $11.81 | -23.46% |
Jul 31, 2025 | $12.37 | $13.14 | +6.22% |
May 05, 2025 | $16.85 | $13.28 | -21.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Integra Lifesciences Holdings Corp. (IART) report earnings?
Integra Lifesciences Holdings Corp. (IART) is schdueled to report earning on Apr 29, 2026, Before Open (Confirmed).
What is Integra Lifesciences Holdings Corp. (IART) earnings time?
Integra Lifesciences Holdings Corp. (IART) earnings time is at Apr 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IART EPS forecast?
IART EPS forecast for the fiscal quarter 2026 (Q1) is 0.4.